



CS/NSE/BSE/PR/2015-2016  
February 19, 2016

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

To  
The General Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

**Sub: Press Release**

.....  
With reference to above subject, please find enclosed Press Release of our company titled “**Suven Life Sciences secures two (2) Product Patents in Australia and Canada.**”

This is for your information and records.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

  
**K Hanumantha Rao**  
Company Secretary

**Suven Life Sciences Limited**

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

## News Release

### Suven Life Sciences secures two (2) Product Patents in Australia and Canada

HYDERABAD, INDIA (February 19, 2016) – Suven Life Sciences Ltd (Suven) announces today that the grant of **one (1) product patent from Australia (2012311057) and one (1) product patent from Canada (2827567)** corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032 and 2031 respectively.

The granted claims of the patent from **Australia** include **the class of selective 5-HT<sub>4</sub> compounds and the granted claims of the patent from Canada is through mechanism of action – H<sub>3</sub> Inverse agonist** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of **twenty three (23) granted patents from Australia and twenty two (22) granted product patents from Canada**. These granted patents are exclusive intellectual property of Suven and are achieved through the **internal discovery research** efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

**“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally”** says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.**

For more information please visit our Web site at <http://www.suven.com>

**Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.***

## Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)